These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

74 related articles for article (PubMed ID: 1323073)

  • 1. Effect of bezafibrate on lipoprotein (a) and triglyceride-rich lipoproteins, including intermediate-density lipoproteins, in patients with chronic renal failure receiving haemodialysis.
    Pelegrí A; Romero R; Sentí M; Nogués X; Pedro-Botet J; Rubiés-Prat J
    Nephrol Dial Transplant; 1992; 7(7):623-6. PubMed ID: 1323073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of two different fibric acid derivatives on lipoproteins, cholesteryl ester transfer, fibrinogen, plasminogen activator inhibitor and paraoxonase activity in type IIb hyperlipoproteinaemia.
    Durrington PN; Mackness MI; Bhatnagar D; Julier K; Prais H; Arrol S; Morgan J; Wood GN
    Atherosclerosis; 1998 May; 138(1):217-25. PubMed ID: 9678787
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of bezafibrate on very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL), and low density lipoprotein (LDL) composition in type 1 diabetes associated with hypercholesterolaemia or combined hyperlipidaemia.
    Winocour PH; Durrington PN; Bhatagnar D; Ishola M; Mackness M; Arrol S; Anderson DC
    Atherosclerosis; 1992 Mar; 93(1-2):83-94. PubMed ID: 1596307
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lipoprotein profile in men with peripheral vascular disease. Role of intermediate density lipoproteins and apoprotein E phenotypes.
    Sentí M; Nogués X; Pedro-Botet J; Rubiés-Prat J; Vidal-Barraquer F
    Circulation; 1992 Jan; 85(1):30-6. PubMed ID: 1728461
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Abnormal lipid and apolipoprotein composition of major lipoprotein density classes in patients with chronic renal failure.
    Attman PO; Alaupovic P; Tavella M; Knight-Gibson C
    Nephrol Dial Transplant; 1996 Jan; 11(1):63-9. PubMed ID: 8649654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure.
    Sentí M; Romero R; Pedro-Botet J; Pelegrí A; Nogués X; Rubiés-Prat J
    Kidney Int; 1992 May; 41(5):1394-9. PubMed ID: 1614054
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Increased lipoprotein-remnant formation in chronic renal failure.
    Nestel PJ; Fidge NH; Tan MH
    N Engl J Med; 1982 Aug; 307(6):329-33. PubMed ID: 7088097
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of slow-release bezafibrate on serum lipids, lipoproteins, apolipoproteins, and postheparin lipolytic activities in patients with type IV and type V hypertriglyceridemia.
    Saku K; Sasaki J; Arakawa K
    Clin Ther; 1989; 11(3):331-40. PubMed ID: 2743372
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency.
    Lee DM; Knight-Gibson C; Samuelsson O; Attman PO; Wang CS; Alaupovic P
    Kidney Int; 2002 Jan; 61(1):209-18. PubMed ID: 11786103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reduction of intermediate density lipoprotein by pravastatin in hemo- and peritoneal dialysis patients.
    Nishizawa Y; Shoji T; Emoto M; Kawasaki K; Konishi T; Tabata T; Inoue T; Morii H
    Clin Nephrol; 1995 Apr; 43(4):268-77. PubMed ID: 7606882
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bezafibrate retard in patients with insulin-dependent diabetes: effect on serum lipoproteins, fibrinogen, and glycemic control.
    Durrington PN; Winocour PH; Bhatnagar D
    J Cardiovasc Pharmacol; 1990; 16 Suppl 9():S30-4. PubMed ID: 1710743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Apolipoprotein B-containing lipoproteins in renal failure: the relation to mode of dialysis.
    Attman PO; Samuelsson OG; Moberly J; Johansson AC; Ljungman S; Weiss LG; Knight-Gibson C; Alaupovic P
    Kidney Int; 1999 Apr; 55(4):1536-42. PubMed ID: 10201020
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Two subpopulations of intermediate density lipoprotein and their relationship to plasma triglyceride and cholesterol levels.
    Meyer BJ; Caslake MJ; McConnell MM; Packard CJ
    Atherosclerosis; 2000 Dec; 153(2):355-62. PubMed ID: 11164424
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Abnormal fat metabolism in chronic renal failure.
    Romics L; Makó J
    Acta Med Acad Sci Hung; 1978; 35(3-4):233-40. PubMed ID: 227218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased concentrations of Apo B-containing triglyceride-rich lipoprotein particles in patients with chronic renal failure.
    Attman PO; Knight-Gibson C; Tavella M; Samuelsson O; Alaupovic P
    Miner Electrolyte Metab; 1992; 18(2-5):199-202. PubMed ID: 1465058
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Abnormalities in very low, low and high density lipoproteins in hypertriglyceridemia. Reversal toward normal with bezafibrate treatment.
    Eisenberg S; Gavish D; Oschry Y; Fainaru M; Deckelbaum RJ
    J Clin Invest; 1984 Aug; 74(2):470-82. PubMed ID: 6378975
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipoprotein subfraction changes in normal pregnancy: threshold effect of plasma triglyceride on appearance of small, dense low density lipoprotein.
    Sattar N; Greer IA; Louden J; Lindsay G; McConnell M; Shepherd J; Packard CJ
    J Clin Endocrinol Metab; 1997 Aug; 82(8):2483-91. PubMed ID: 9253322
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of L-carnitine on the serum lipoproteins and HDL-C subclasses in hemodialysis patients.
    Argani H; Rahbaninoubar M; Ghorbanihagjo A; Golmohammadi Z; Rashtchizadeh N
    Nephron Clin Pract; 2005; 101(4):c174-9. PubMed ID: 16103722
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of ciprofibrate on lipoproteins, fibrinogen, renal function, and hepatic enzymes.
    Rizos E; Bairaktari E; Ganotakis E; Tsimihodimos V; Mikhailidis DP; Elisaf M
    J Cardiovasc Pharmacol Ther; 2002 Oct; 7(4):219-26. PubMed ID: 12490967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of uremic hypertriglyceridaemia with bezafibrate.
    Norbeck HE; Anderson P
    Atherosclerosis; 1982 Aug; 44(2):125-36. PubMed ID: 7138614
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.